Voloridge Investment Management LLC acquired a new stake in shares of China Biologic Products Holdings Inc (NASDAQ:CBPO) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 23,849 shares of the biopharmaceutical company’s stock, valued at approximately $2,730,000.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. York Capital Management Global Advisors LLC raised its stake in China Biologic Products by 13.9% during the 2nd quarter. York Capital Management Global Advisors LLC now owns 1,128,717 shares of the biopharmaceutical company’s stock worth $107,567,000 after acquiring an additional 137,484 shares during the period. Canada Pension Plan Investment Board purchased a new position in China Biologic Products during the second quarter valued at approximately $8,749,000. Point72 Asset Management L.P. purchased a new position in China Biologic Products during the second quarter valued at approximately $6,477,000. Nikko Asset Management Americas Inc. boosted its position in shares of China Biologic Products by 101.4% in the second quarter. Nikko Asset Management Americas Inc. now owns 109,599 shares of the biopharmaceutical company’s stock worth $10,445,000 after purchasing an additional 55,176 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of China Biologic Products by 3.2% in the second quarter. Vanguard Group Inc. now owns 950,421 shares of the biopharmaceutical company’s stock worth $90,575,000 after purchasing an additional 29,178 shares during the period. 38.66% of the stock is owned by institutional investors.
A number of analysts have recently issued reports on the stock. Zacks Investment Research cut shares of China Biologic Products from a “buy” rating to a “hold” rating in a research note on Thursday, October 24th. ValuEngine raised shares of China Biologic Products from a “hold” rating to a “buy” rating in a report on Tuesday, October 1st. Finally, BidaskClub lowered China Biologic Products from a “hold” rating to a “sell” rating in a research report on Thursday, November 28th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $92.67.
China Biologic Products (NASDAQ:CBPO) last issued its earnings results on Wednesday, November 13th. The biopharmaceutical company reported $1.40 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.52. The firm had revenue of $136.10 million during the quarter. China Biologic Products had a net margin of 31.22% and a return on equity of 9.79%. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.96 earnings per share. As a group, equities research analysts forecast that China Biologic Products Holdings Inc will post 3.29 earnings per share for the current fiscal year.
China Biologic Products Profile
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
See Also: What is range trading?
Want to see what other hedge funds are holding CBPO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for China Biologic Products Holdings Inc (NASDAQ:CBPO).
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.